Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world’s first oral GLP-1RA. This study aimed to provide real...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Journal of Cardiovascular Development and Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2308-3425/10/4/176 |
| _version_ | 1797604934081839104 |
|---|---|
| author | Hodaka Yamada Masashi Yoshida Shunsuke Funazaki Jun Morimoto Shiori Tonezawa Asuka Takahashi Shuichi Nagashima Kimura Masahiko Otsuka Kiyoshi Kazuo Hara |
| author_facet | Hodaka Yamada Masashi Yoshida Shunsuke Funazaki Jun Morimoto Shiori Tonezawa Asuka Takahashi Shuichi Nagashima Kimura Masahiko Otsuka Kiyoshi Kazuo Hara |
| author_sort | Hodaka Yamada |
| collection | DOAJ |
| description | Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world’s first oral GLP-1RA. This study aimed to provide real-world data on oral semaglutide in Japanese patients with T2DM and its effects on cardiometabolic parameters. This was a single-center retrospective observational study. We examined changes in HbA1c and body weight (BW) and the rate of achieving HbA1c < 7% after 6 months of oral semaglutide treatment in Japanese patients with T2DM. Furthermore, we examined differences in the efficacy of oral semaglutide with multiple patient backgrounds. A total of 88 patients were included in this study. Overall, the mean (standard error of the mean) HbA1c at 6 months decreased by −1.24% (0.20%) from baseline, and BW at 6 months (<i>n</i> = 85) also decreased by −1.44 kg (0.26 kg) from baseline. The percentage of patients who achieved HbA1c < 7% changed significantly from 14% at baseline to 48%. HbA1c decreased from baseline regardless of age, sex, body mass index, chronic kidney disease, or diabetes duration. Additionally, alanine aminotransferase, total cholesterol, triglyceride, and non-high-density lipoprotein cholesterol were significantly reduced from baseline. Oral semaglutide may be an effective option for the intensification of therapy in Japanese patients with T2DM who have inadequate glycemic control with existing therapy. It may also reduce BW and improve cardiometabolic parameters. |
| first_indexed | 2024-03-11T04:53:52Z |
| format | Article |
| id | doaj.art-3f026c56c7f2462fb48b48d96eda9935 |
| institution | Directory Open Access Journal |
| issn | 2308-3425 |
| language | English |
| last_indexed | 2024-03-11T04:53:52Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Cardiovascular Development and Disease |
| spelling | doaj.art-3f026c56c7f2462fb48b48d96eda99352023-11-17T19:47:52ZengMDPI AGJournal of Cardiovascular Development and Disease2308-34252023-04-0110417610.3390/jcdd10040176Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical SettingsHodaka Yamada0Masashi Yoshida1Shunsuke Funazaki2Jun Morimoto3Shiori Tonezawa4Asuka Takahashi5Shuichi Nagashima6Kimura Masahiko7Otsuka Kiyoshi8Kazuo Hara9Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Pharmacy, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Pharmacy, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanDepartment of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, JapanGlucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world’s first oral GLP-1RA. This study aimed to provide real-world data on oral semaglutide in Japanese patients with T2DM and its effects on cardiometabolic parameters. This was a single-center retrospective observational study. We examined changes in HbA1c and body weight (BW) and the rate of achieving HbA1c < 7% after 6 months of oral semaglutide treatment in Japanese patients with T2DM. Furthermore, we examined differences in the efficacy of oral semaglutide with multiple patient backgrounds. A total of 88 patients were included in this study. Overall, the mean (standard error of the mean) HbA1c at 6 months decreased by −1.24% (0.20%) from baseline, and BW at 6 months (<i>n</i> = 85) also decreased by −1.44 kg (0.26 kg) from baseline. The percentage of patients who achieved HbA1c < 7% changed significantly from 14% at baseline to 48%. HbA1c decreased from baseline regardless of age, sex, body mass index, chronic kidney disease, or diabetes duration. Additionally, alanine aminotransferase, total cholesterol, triglyceride, and non-high-density lipoprotein cholesterol were significantly reduced from baseline. Oral semaglutide may be an effective option for the intensification of therapy in Japanese patients with T2DM who have inadequate glycemic control with existing therapy. It may also reduce BW and improve cardiometabolic parameters.https://www.mdpi.com/2308-3425/10/4/176glucagon-like peptide-1 receptor agonistoral semaglutidetype 2 diabetes mellitusreal-world datacardiometabolic risk factors |
| spellingShingle | Hodaka Yamada Masashi Yoshida Shunsuke Funazaki Jun Morimoto Shiori Tonezawa Asuka Takahashi Shuichi Nagashima Kimura Masahiko Otsuka Kiyoshi Kazuo Hara Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings Journal of Cardiovascular Development and Disease glucagon-like peptide-1 receptor agonist oral semaglutide type 2 diabetes mellitus real-world data cardiometabolic risk factors |
| title | Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings |
| title_full | Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings |
| title_fullStr | Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings |
| title_full_unstemmed | Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings |
| title_short | Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings |
| title_sort | retrospective analysis of the effectiveness of oral semaglutide in type 2 diabetes mellitus and its effect on cardiometabolic parameters in japanese clinical settings |
| topic | glucagon-like peptide-1 receptor agonist oral semaglutide type 2 diabetes mellitus real-world data cardiometabolic risk factors |
| url | https://www.mdpi.com/2308-3425/10/4/176 |
| work_keys_str_mv | AT hodakayamada retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT masashiyoshida retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT shunsukefunazaki retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT junmorimoto retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT shioritonezawa retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT asukatakahashi retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT shuichinagashima retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT kimuramasahiko retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT otsukakiyoshi retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings AT kazuohara retrospectiveanalysisoftheeffectivenessoforalsemaglutideintype2diabetesmellitusanditseffectoncardiometabolicparametersinjapaneseclinicalsettings |